GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TuHURA Biosciences Inc (NAS:HURA) » Definitions » Total Stockholders Equity

HURA (TuHURA Biosciences) Total Stockholders Equity : $14.59 Mil (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is TuHURA Biosciences Total Stockholders Equity?

TuHURA Biosciences's Total Stockholders Equity for the quarter that ended in Dec. 2024 was $14.59 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. TuHURA Biosciences's Book Value per Share for the quarter that ended in Dec. 2024 was $0.34. The ratio of a company's debt over equity can be used to measure how leveraged this company is. TuHURA Biosciences's Debt-to-Equity for the quarter that ended in Dec. 2024 was 0.01.

TuHURA Biosciences Total Stockholders Equity Historical Data

The historical data trend for TuHURA Biosciences's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TuHURA Biosciences Total Stockholders Equity Chart

TuHURA Biosciences Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Total Stockholders Equity
-0.75 12.30 -1.56 14.59

TuHURA Biosciences Quarterly Data
Dec21 Mar22 Dec22 Mar23 Dec23 Mar24 Jun24 Sep24 Dec24
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only -1.56 -6.07 -6.96 1.70 14.59

TuHURA Biosciences  (NAS:HURA) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

TuHURA Biosciences's Book Value per Share for the quarter that ended in Dec. 2024 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(14.594-0.279)/42.324
=0.34

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

TuHURA Biosciences's Debt-to-Equity for the quarter that ended in Dec. 2024 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.16 + 0.043) / 14.594
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TuHURA Biosciences Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of TuHURA Biosciences's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

TuHURA Biosciences Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TuHURA Biosciences Inc (NAS:HURA) » Definitions » Total Stockholders Equity
Comparable Companies
INMB INBX SGMO TVRD TVGN RGLS ACTU DMAC YMAB DRTS VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
10500 University Center Drive, Suite 110, Tampa, FL, USA, 33612
Website
https://www.tuhurabio.com
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.